Operation Brain Trauma Therapy (OBTT) is a multisite research consortium composed of investigators from several internationally recognized research centers that was created  in 2011 to respond to the need for novel therapies and biomarkers in traumatic brain injury (TBI). OBTT was designed to serve as a high-throughput therapy screening research consortium that identifies the most promising therapies and compares them across a spectrum of the state-of-the-art models and injury levels. The most promising therapies are moved up the phylogenetic scale. OBTT then recommends agents that are either U.S. Food and Drug Administration (FDA) approved for other uses, or are in clinical development that are found to be effective across models for rapid clinical translation to the US Army. OBTT is structured to allow a direct comparison of therapies across TBI models in multiple centers. It also includes a comparison of therapies across highly relevant combat casualty care scenarios. OBTT is supported by the United States Army grant W81XWH-10-1-0623. OBTT is composed of the seven sites below.